Table 1. Clinical outcomes in Group A and Group B at baseline, 1wk and 1mo.
| Parameters | Group | Baseline | 1wk | 1mo |
| OSDI | A | 38.92±2.59 | 29.98±3.31a | 25.72±4.52b |
| B | 38.14±2.39 | 31.07±2.44b | 21.48±4.79b | |
| TBUT(s) | A | 4.17±0.31 | 5.34±0.37b | 5.87±0.44b,d |
| B | 3.80±0.28 | 4.71±0.33a | 4.63±0.31a | |
| CFS | A | 2.24±0.42 | 1.39±0.34a | 1.18±0.35a |
| B | 2.85±0.49 | 1.68±0.41b | 1.24±0.38a | |
| MGE | A | 3.71±0.20 | 2.63±0.19c | 1.61±0.15b,e |
| B | 3.80±0.21 | 3.12±0.22b | 2.61±0.23b | |
| Meibum quality | A | 2.22±0.22 | 2.00±0.20 | 2.53±0.32 |
| B | 2.54±0.22 | 2.15±0.20 | 2.94±0.33 | |
| Gland dropout | A | 3.80±0.17 | 3.80±0.13 | 4.18±0.21 |
| B | 3.87±0.13 | 3.70±0.11 | 4.12±0.19 |
OSDI: Ocular surface disease index; TBUT: Tear film breakup time; CFS: Corneal fluorescein staining; MGE: Meibomian gland expressibility. aP<0.05, bP<0.01, cP<0.001, comparing with baseline. dP<0.05, eP<0.01, comparing Group A with Group B.